Ticagrelor - CAS 274693-27-5

Ticagrelor (AR-C 126532XX), produced by AstraZeneca, is an inhibitor of platelet aggregation. Unlike clopidogrel, ticagrelor is not a prodrug required metabolic activation. The drug was approved for use in the European Union by the European Commission on December 3, 2010, and by the US FDA on July 20, 2011. Its trade names are Brilinta (US), Brilique (EU) and Possia (EU) .

Cytochromes P450, P2Y Receptor

Metabolism, Neuroscience, GPCR/G Protein

274661

>99.99%

C23H28F2N6O4S

522.57

CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1

-20°C

Ice Packs

Small Compound